00:02 , Mar 7, 2019 |  BC Extra  |  Clinical News

Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD). Allergan plc (NYSE:AGN) is also conducting a Phase...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
01:27 , Dec 30, 2016 |  BioCentury  |  Emerging Company Profile

Mining for substitutions

Riptide Bioscience Inc. has mined the sequences and structures of failed first-generation peptide therapeutics to engineer a new class of host defense peptides with amino acid substitutions that could make its candidates more effective in...
07:00 , May 5, 2016 |  BC Innovations  |  Targets & Mechanisms

Better call Delilah

Long non-coding RNAs (lncRNAs), once confined to the pile of non-functional genomic "junk," are now recognized to play key roles in gene regulation, and are increasingly being explored in various cancers. A Belgian group has...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

DP-VPA regulatory update

D-Pharm said partner Jiangsu NHWA received notice that China Food and Drug Administration (CFDA) granted Fast Track designation to DP-VPA to treat epilepsy. D-Pharm said Jiangsu NHWA plans to begin a Phase I trial in...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Epratuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of epratuzumab-RAP...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Veltuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed that weekly 200 mg/m 2 IV veltuzumab-RAP for 4 weeks in combination with 2 infusions of epratuzumab-RAP...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

D-Pharm, Jiangsu NHWA deal

D-Pharm received a $1 million milestone payment from Jiangsu NHWA under a 2011 deal that granted Jiangsu NHWA exclusive rights to develop and commercialize DP-VPA in China for epilepsy. The milestone payment is the first...
08:00 , Mar 5, 2012 |  BC Week In Review  |  Company News

D-Pharm, Thrombotech deal

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted...
02:16 , Feb 28, 2012 |  BC Extra  |  Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal after discontinuing development of its own stroke therapy last month due to lack...